X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-07 | YMAB | Y-Mabs Therapeutics, Inc. | Rossi Michael J | Pres, CEO | S - Sale | $5.20 | -3,917 | 137,083 | -3% | -$20,368 | ||||||
2025-03-07 | YMAB | Y-Mabs Therapeutics, Inc. | Gad Thomas | CHIEF BUSINESS OFFICER | S - Sale | $5.23 | -10,810 | 330,402 | -3% | -$56,536 | ||||||
2025-03-11 | DERM | Journey Medical Corp | Maraoui Claude | Pres, CEO | S - Sale | $5.01 | -49,271 | 2,003,147 | -2% | -$246,848 | ||||||
| D | 2025-03-10 | CYRX | Cryoport, Inc. | Sawicki Mark W | Chief Scientific Officer | S - Sale+OE | $4.88 | -1,583 | 78,528 | -2% | -$7,724 | |||||
| D | 2025-03-10 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $4.88 | -4,173 | 740,019 | -1% | -$20,360 | |||||
| D | 2025-03-10 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale+OE | $4.88 | -1,256 | 183,078 | -1% | -$6,128 | |||||
2025-03-11 | ABCL | Abcellera Biologics Inc. | Thermopylae Holdings Ltd. | 10% | P - Purchase | $2.16 | +343,631 | 56,143,640 | +1% | +$742,243 | ||||||
2025-03-10 | JAZZ | Jazz Pharmaceuticals Plc | Carr Patricia | SVP, Chief Accounting Officer | S - Sale | $137.81 | -1,140 | 7,012 | -14% | -$157,103 | ||||||
2025-03-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $21.44 | -6,667 | 323,310 | -2% | -$142,936 | ||||||
| M | 2025-03-07 | ELAN | Elanco Animal Health Inc | Kurzius Lawrence Erik | Dir | P - Purchase | $10.55 | +20,000 | 111,459 | +22% | +$211,000 | |||||
| D | 2025-03-07 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $30.02 | -200 | 14,863 | -1% | -$6,004 | |||||
| D | 2025-03-07 | EWTX | Edgewise Therapeutics, Inc. | Koch Kevin | Pres, CEO | S - Sale+OE | $30.00 | -100 | 353,262 | 0% | -$3,000 | |||||
| D | 2025-03-10 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $320.09 | -2,000 | 2,648 | -43% | -$640,184 | |||||
2025-03-10 | XNCR | Xencor Inc | Valente Nancy | EVP, Chief Development Officer | S - Sale | $13.60 | -2,565 | 53,785 | -5% | -$34,877 | ||||||
2025-03-10 | XNCR | Xencor Inc | Eckert Celia | SVP, GC | S - Sale | $13.60 | -5,740 | 63,507 | -8% | -$78,047 | ||||||
2025-03-10 | XNCR | Xencor Inc | Desjarlais John R | SVP, CSO | S - Sale | $13.60 | -9,697 | 236,574 | -4% | -$131,851 | ||||||
2025-03-10 | XNCR | Xencor Inc | Dahiyat Bassil I | Pres, CEO | S - Sale | $13.60 | -19,716 | 465,419 | -4% | -$268,080 | ||||||
2025-03-10 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale | $170.00 | -326 | 16,593 | -2% | -$55,420 | ||||||
2025-03-11 | ZTS | Zoetis Inc. | Reed Willie M | Dir | S - Sale | $166.14 | -1,210 | 11,245 | -10% | -$201,029 | ||||||
| M | 2025-03-07 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $10.19 | -4,000 | 2,839,260 | 0% | -$40,776 | |||||
2025-03-10 | ETST | Earth Science Tech, Inc. | Tabraue Mario Guillermo | COO | P - Purchase | $0.14 | +40,000 | 12,422,023 | 0% | +$5,600 | ||||||
2025-03-07 | DVAX | Dynavax Technologies Corp | Novack David F | Pres, COO | S - Sale | $14.39 | -32,764 | 22,098 | -60% | -$471,474 | ||||||
2025-03-07 | ANIP | Ani Pharmaceuticals Inc | Davis Krista | SVP, CHRO | S - Sale | $60.86 | -1,000 | 66,525 | -1% | -$60,860 | ||||||
| D | 2025-03-10 | PRGO | Perrigo Co Plc | Janish Ronald Craig | EVP, Gbl Ops, SC, CTO | S - Sale+OE | $27.44 | -7,800 | 33,666 | -19% | -$214,032 | |||||
| D | 2025-03-07 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $11.97 | -6,669 | 287,811 | -2% | -$79,828 | |||||
| M | 2025-03-06 | DERM | Journey Medical Corp | Maraoui Claude | Pres, CEO | S - Sale | $5.03 | -40,456 | 2,052,418 | -2% | -$203,451 | |||||
| M | 2025-03-06 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $43.69 | +1,915 | 3,732,737 | 0% | +$83,661 | |||||
2025-03-10 | ABCL | Abcellera Biologics Inc. | Montalbano John S. | Dir | P - Purchase | $2.30 | +25,000 | 176,000 | +17% | +$57,500 | ||||||
| DM | 2025-03-06 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $71.87 | -34,000 | 48,034 | -41% | -$2,443,578 | |||||
| D | 2025-03-06 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale+OE | $32.58 | -12,875 | 5,197 | -71% | -$419,500 | |||||
2025-03-07 | SEPN | Septerna, Inc. | Ezekowitz Alan | Dir | P - Purchase | $6.93 | +13,319 | 117,420 | +13% | +$92,270 | ||||||
| A | 2024-09-27 | BIOA | Bioage Labs, Inc. | Hemrajani Rekha | Dir | P - Purchase | $18.00 | +3,000 | 3,000 | New | +$54,000 | |||||
2024-09-27 | BIOA | Bioage Labs, Inc. | Barton Shane | Principal Accounting Officer | P - Purchase | $18.00 | +2,632 | 2,632 | New | +$47,376 | ||||||
| M | 2025-03-06 | COLL | Collegium Pharmaceutical, Inc | Tupper Colleen | EVP, CFO | S - Sale | $30.00 | -3,453 | 175,691 | -2% | -$103,591 | |||||
| M | 2025-03-06 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale | $30.00 | -5,643 | 142,063 | -4% | -$169,299 | |||||
2025-03-06 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $40.40 | -1,785 | 106,169 | -2% | -$72,114 | ||||||
| D | 2025-03-07 | WVE | Wave Life Sciences Ltd. | Bolno Paul | Pres, CEO | S - Sale+OE | $9.57 | -169,025 | 338,351 | -33% | -$1,617,569 | |||||
2025-03-06 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $43.27 | -3,341 | 64,434 | -5% | -$144,565 | ||||||
2025-03-06 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $43.27 | -8,228 | 105,394 | -7% | -$356,026 | ||||||
2025-03-06 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $43.44 | -16,970 | 368,347 | -4% | -$737,177 | ||||||
| D | 2025-03-07 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale+OE | $249.13 | -58,590 | 51,656,119 | 0% | -$14,596,247 | |||||
| D | 2025-03-06 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale+OE | $259.15 | -40,109 | 50,947,372 | 0% | -$10,394,329 | |||||
| D | 2025-03-07 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $5.36 | -41,668 | 1,660,502 | -2% | -$223,199 | |||||
| D | 2025-03-05 | BGNE | Beigene, Ltd. | Wu Xiaobin | Pres, COO, GM China | S - Sale+OE | $261.59 | -51,921 | 1,191,575 | -4% | -$13,581,905 | |||||
| DM | 2025-03-06 | ABT | Abbott Laboratories | Earnhardt Lisa D | EVP, GROUP Pres | S - Sale+OE | $133.83 | -91,367 | 71,928 | -56% | -$12,227,297 | |||||
2025-03-07 | JAZZ | Jazz Pharmaceuticals Plc | Iannone Robert | EVP, Global Head of R, D, CMO | S - Sale | $138.60 | -7,080 | 82,024 | -8% | -$981,298 | ||||||
| M | 2025-03-05 | JANX | Janux Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $30.75 | +824,041 | 11,189,693 | +8% | +$25,342,965 | |||||
| D | 2025-03-05 | MDGL | Madrigal Pharmaceuticals, Inc. | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $341.32 | -14,113 | 5,789 | -71% | -$4,817,104 | |||||
| D | 2025-03-05 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $44.53 | -12,500 | 170,237 | -7% | -$556,590 | |||||
2025-03-07 | AUPH | Aurinia Pharmaceuticals Inc. | Keenan Greg | Chief Medical Officer | S - Sale | $8.23 | -8,305 | 153,484 | -5% | -$68,350 | ||||||
| DM | 2025-03-05 | SPRY | Ars Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $11.21 | -50,000 | 210,346 | -19% | -$560,446 | |||||
| DM | 2025-03-05 | CPRX | Catalyst Pharmaceuticals, Inc. | Ingenito Gary | Chief Med., Reg. Officer | S - Sale+OE | $21.75 | -225,000 | 68,873 | -77% | -$4,894,610 | |||||
2025-03-06 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Smethurst Dominic | Chief Medical Officer | S - Sale | $6.78 | -6,393 | 70,807 | -8% | -$43,330 | ||||||
2025-03-05 | ELAN | Elanco Animal Health Inc | Hoover R David | Dir | P - Purchase | $10.90 | +25,000 | 322,379 | +8% | +$272,558 | ||||||
2025-03-05 | AMRX | Amneal Pharmaceuticals, Inc. | Boyer Andrew S | EVP | S - Sale | $8.89 | -125,000 | 290,106 | -30% | -$1,111,250 | ||||||
| M | 2025-03-05 | AMRX | Amneal Pharmaceuticals, Inc. | Daly Jason B. | EVP, GC | S - Sale | $8.80 | -90,000 | 32,606 | -73% | -$792,160 | |||||
2025-03-05 | AMRX | Amneal Pharmaceuticals, Inc. | Konidaris Tasos | EVP, CFO | S - Sale | $8.91 | -100,000 | 621,882 | -14% | -$891,000 | ||||||
2025-03-05 | AMRX | Amneal Pharmaceuticals, Inc. | Alva Emily Peterson | Dir | S - Sale | $8.90 | -80,000 | 170,771 | -32% | -$712,000 | ||||||
| M | 2025-03-05 | BPMC | Blueprint Medicines Corp | Hewes L. Becker | Chief Medical Officer | S - Sale | $88.23 | -10,095 | 30,419 | -25% | -$890,639 | |||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Rossi Christina | COO | S - Sale | $88.80 | -6,495 | 71,540 | -8% | -$576,756 | ||||||
2025-03-06 | SDGR | Schrodinger, Inc. | Herman Jenny | SVP, Controller | S - Sale | $21.11 | -666 | 27,349 | -2% | -$14,059 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Namouni Fouad | Pres, R, D | S - Sale | $88.80 | -6,489 | 75,781 | -8% | -$576,223 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | McCain Tracey L | EVP, GC | S - Sale | $88.80 | -5,262 | 66,583 | -7% | -$467,266 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Lee Philina | CHIEF COMMERCIAL OFFICER | S - Sale | $88.80 | -3,733 | 41,996 | -8% | -$331,490 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Landsittel Michael | CFO | S - Sale | $88.80 | -5,284 | 72,924 | -7% | -$469,219 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale | $88.80 | -1,326 | 16,944 | -7% | -$117,749 | ||||||
| D | 2025-03-05 | ANIP | Ani Pharmaceuticals Inc | Gutwerg Ori | SVP, GENERICS | S - Sale+OE | $60.00 | -5,384 | 94,092 | -5% | -$323,049 | |||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Haviland Kate | CEO | S - Sale | $88.80 | -16,151 | 168,427 | -9% | -$1,434,209 | ||||||
2025-03-05 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $11.83 | -1,343 | 94,157 | -1% | -$15,888 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Durso-Bumpus Debra | Chief People Officer | S - Sale | $88.80 | -5,157 | 49,606 | -9% | -$457,942 | ||||||
2025-03-05 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $11.83 | -4,061 | 178,239 | -2% | -$48,042 | ||||||
2025-03-05 | BPMC | Blueprint Medicines Corp | Carter Percy H. | Chief Scientific Officer | S - Sale | $88.80 | -3,530 | 56,865 | -6% | -$313,464 | ||||||
2025-03-06 | BMRN | Biomarin Pharmaceutical Inc | Guyer Charles Greg | EVP, Chief Technical Officer | S - Sale | $71.28 | -7,034 | 87,655 | -7% | -$501,355 | ||||||
2025-03-05 | DYN | Dyne Therapeutics, Inc. | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $11.83 | -917 | 123,673 | -1% | -$10,848 | ||||||
| D | 2025-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, European Commercial | S - Sale+OE | $15.91 | -70,961 | 48,384 | -59% | -$1,128,642 | |||||
2025-03-05 | DYN | Dyne Therapeutics, Inc. | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $11.83 | -1,094 | 197,993 | -1% | -$12,942 | ||||||
| M | 2025-03-05 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $10.89 | -4,000 | 2,843,260 | 0% | -$43,560 | |||||
2025-03-06 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $27.99 | -1,000 | 74,409 | -1% | -$27,986 | ||||||
2025-03-06 | ABCL | Abcellera Biologics Inc. | Montalbano John S. | Dir | P - Purchase | $2.34 | +60,000 | 151,000 | +66% | +$140,568 | ||||||
2025-03-04 | ETST | Earth Science Tech, Inc. | Rose Christopher Alan | CTO | P - Purchase | $0.16 | +31,500 | 85,151 | +59% | +$4,935 | ||||||
| M | 2025-03-04 | INVA | Innoviva, Inc. | Denner Alexander J | 10% | S - Sale | $17.55 | -1,618,295 | 5,658,705 | -22% | -$28,395,442 | |||||
2025-03-04 | ORGO | Organogenesis Holdings Inc. | Driscoll Michael Joseph | Dir | S - Sale | $5.10 | -25,000 | 166,879 | -13% | -$127,535 | ||||||
| M | 2025-03-04 | SEPN | Septerna, Inc. | Ezekowitz Alan | Dir | P - Purchase | $5.95 | +86,681 | 104,101 | +498% | +$515,934 | |||||
2025-03-04 | APLT | Applied Therapeutics, Inc. | Perfetti Riccardo | Chief Medical Officer | S - Sale | $0.44 | -10,366 | 890,409 | -1% | -$4,561 | ||||||
2025-03-04 | APLT | Applied Therapeutics, Inc. | Funtleyder Leslie D. | See Remarks | S - Sale | $0.44 | -14,502 | 390,459 | -4% | -$6,381 | ||||||
2025-03-04 | APLT | Applied Therapeutics, Inc. | Chinoporos Constantine | See Remarks | S - Sale | $0.44 | -447 | 271,436 | 0% | -$197 | ||||||
| D | 2025-03-04 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale+OE | $115.03 | -5,000 | 26,363 | -16% | -$575,149 | |||||
| DM | 2025-03-04 | COLL | Collegium Pharmaceutical, Inc | Kuhlmann Shirley R. | EVP, GC | S - Sale+OE | $28.19 | -86,067 | 108,137 | -44% | -$2,426,634 | |||||
2025-03-05 | ACAD | Acadia Pharmaceuticals Inc | Garofalo Elizabeth A. | Dir | S - Sale | $18.23 | -4,919 | 17,595 | -22% | -$89,673 | ||||||
2025-03-06 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Pres, CEO | P - Purchase | $5.02 | +10,000 | 2,295,731 | 0% | +$50,150 | ||||||
2025-03-04 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $21.02 | +4,005 | 6,813,434 | 0% | +$84,203 | ||||||
| M | 2025-03-04 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $45.40 | +1,602 | 3,730,822 | 0% | +$72,724 | |||||
2025-03-04 | PTCT | Ptc Therapeutics, Inc. | Jacobson Allan Steven | Dir | S - Sale | $51.52 | -1,230 | 19,118 | -6% | -$63,370 | ||||||
2025-03-05 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $25.10 | -5,569 | 218,866 | -2% | -$139,789 | ||||||
| D | 2025-03-04 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, EVP, Treasurer | S - Sale+OE | $27.54 | -4,231 | 95,624 | -4% | -$116,515 | |||||
2025-03-04 | BGNE | Beigene, Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale | $254.58 | -8,146 | 10,219,095 | 0% | -$2,073,826 | ||||||
2025-03-04 | KPTI | Karyopharm Therapeutics Inc. | Cheng Sohanya Roshan | EVP, Chief Commercial Officer | S - Sale | $6.29 | -3,445 | 34,314 | -9% | -$21,669 | ||||||
2025-03-04 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Pres, CEO | S - Sale | $6.29 | -11,694 | 82,984 | -12% | -$73,555 | ||||||
2025-03-04 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | EVP, Chief Medical Officer | S - Sale | $6.29 | -3,587 | 29,272 | -11% | -$22,562 | ||||||
2025-03-04 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | EVP, Chief Development Officer | S - Sale | $6.29 | -3,548 | 27,414 | -11% | -$22,317 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |